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Abstract
Contagious bovine pleuropneumonia has been assessed according to the criteria of the Animal Health
Law (AHL), in particular criteria of Article 7 on disease proﬁle and impacts, Article 5 on the eligibility of
contagious bovine pleuropneumonia to be listed, Article 9 for the categorisation of contagious bovine
pleuropneumonia according to disease prevention and control rules as in Annex IV and Article 8 on the
list of animal species related to contagious bovine pleuropneumonia. The assessment has been
performed following a methodology composed of information collection and compilation, expert
judgement on each criterion at individual and, if no consensus was reached before, also at collective
level. The output is composed of the categorical answer, and for the questions where no consensus
was reached, the different supporting views are reported. Details on the methodology used for this
assessment are explained in a separate opinion. According to the assessment performed, contagious
bovine pleuropneumonia can be considered eligible to be listed for Union intervention as laid down in
Article 5(3) of the AHL. The disease would comply with the criteria as in Sections 4 and 5 of Annex IV
of the AHL, for the application of the disease prevention and control rules referred to in points (d) and
(e) of Article 9(1). The animal species to be listed for contagious bovine pleuropneumonia according to
Article 8(3) criteria are species of the family Bovidae as susceptible.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
The background and Terms of Reference (ToR) as provided by the European Commission for the
present document are reported in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria
of Article 5, Annex IV according to Article 9, and 8 within the Animal Health Law (AHL) framework
(EFSA AHAW Panel, 2017).
1.2. Interpretation of the Terms of Reference
The interpretation of the ToR is as in Section 1.2 of the scientiﬁc opinion on the ad hoc methodology
followed for the assessment of the disease to be listed and categorised according to the criteria of Article
5, Annex IV according to Article 9, and 8 within the AHL framework (EFSA AHAW Panel, 2017).
The present document reports the results of assessment on contagious bovine pleuropneumonia
(CBPP) according to the criteria of the AHL articles as follows:
• Article 7: contagious bovine pleuropneumonia proﬁle and impacts;
• Article 5: eligibility of contagious bovine pleuropneumonia to be listed;
• Article 9: categorisation of contagious bovine pleuropneumonia according to disease prevention
and control rules as in Annex IV;
• Article 8: list of animal species related to contagious bovine pleuropneumonia.
2. Data and methodologies
The methodology applied in this opinion is described in detail in a dedicated document about the
ad hoc method developed for assessing any animal disease for the listing and categorisation of
diseases within the AHL framework (EFSA AHAW Panel, 2017).
3. Assessment
3.1. Assessment according to Article 7 criteria
This section presents the assessment of CBPP according to the Article 7 criteria of the AHL and
related parameters (see Table 2 of the opinion on methodology (EFSA AHAW Panel, 2017)), based on
the information contained in the fact-sheet as drafted by the selected disease scientist (see Section 2.1
of the scientiﬁc opinion on the ad hoc methodology) and amended by the AHAW Panel.
3.1.1. Article 7(a) Disease Proﬁle
Contagious bovine pleuropneumonia is an infectious and contagious respiratory disease affecting
Bovidae (bovines, yaks and water buffaloes) and caused by a wall-less bacteria (Mollicute):
Mycoplasma mycoides subsp. mycoides (Mmm). It is characterised by a unilateral acute inﬂammation
in the lung and pleural cavity of susceptible animals leading to large quantities of infective droplets
being excreted when the animals are coughing. In the chronic stage lesions consist of necrotic lung
tissue encapsulated by a ﬁbrous tissue, called a sequestrum. Animals with those chronic lesions may
still harbour Mmm and cause the long term persistence and possible shedding of Mmm.
3.1.1.1. Article 7(a)(i) Animal species concerned by the disease
Susceptible animal species
Parameter 1 – Naturally susceptible wildlife species (or family/orders)
No naturally susceptible wild species are identiﬁed. Although slightly positive complement ﬁxation
tests (CFT) have been recorded from wildebeest and hippopotami (Shifrine and Domermuth, 1967),
subcutaneous inoculation of live Mycoplasma did not induce any typical lesion as compared to control
bovines inoculated in parallel, so these species are not likely natural hosts despite these ﬁndings.
Positive complement ﬁxation tests have been detected only in camels (Paling et al., 1988) but no
mycoplasmas were isolated from nasal secretions from camels or buffaloes, which is similar to ﬁndings
in American camelids (Hung et al., 1991). While CFT was performed with a crude antigen, it is highly
probable that the positives were in fact cross-reactors with other mycoplasmas or bacteria.
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Parameter 2 – Naturally susceptible domestic species (or family/orders)
The following species are susceptible to disease: cattle (Bos taurus), yak (Bos gruniensis) (Xin
et al., 2012), and water buffalo (Bubalus bubalis) (Santini et al., 1992). Susceptibility has been
deemed lower in water buffalo compared to cattle, while water buffaloes in contact with Mmm-infected
cattle presented typical lesions from which Mmm could be re-isolated (Provost, 1988).
The following small ruminant species have been identiﬁed as susceptible to infection, based on
exceptional isolations of Mmm: goats in Nigeria (Perreau, 1971); sheep and goats in Portugal
(Brandao, 1995) and goats in India (Srivastava et al., 2000).
Parameter 3 – Experimentally susceptible wildlife species (or family/orders)
African buffalo (Sincerus cafer) (Shifrine et al., 1970) has been experimentally infected with
subcutaneous inoculation of Mmm sometimes leading to re-isolation of Mmm, 53 days after
inoculation, although no gross lesions were observed.
Parameter 4 – Experimentally susceptible domestic species (or family/orders)
Furthermore, among domestic species, sheep and goats have been experimentally infected in
France (Dujardin-Beaumetz, 1906), and goats in Cameroon (Yaya et al., 2000), inducing peritonitis
after intra-abdominal inoculation.
Rabbits have been used to grow Mmm for vaccine development and showed some degree of
susceptibility after multiple passages in China (Xin et al., 2012).
Reservoir animal species
Parameter 5 – Wild reservoir species (or family/orders)
There is no natural wildlife reservoir known so far.
Parameter 6 – Domestic reservoir species (or family/orders)
So far no domestic reservoir species has been identiﬁed. However, CBPP outbreaks have occurred in
Europe at regular intervals (1956; 1967; 1982–1999) without detection of cases in-between the
outbreaks. Molecular studies have shown that these outbreaks were caused by Mmm strains of
European origin (Dupuy et al., 2012). Hence, Mmm strains must have stayed hidden in an unidentiﬁed
carrier host e.g. small ruminants not showing symptoms or cattle harbouring low-pathogenic strains
before reversion to virulence or other, although the source remained unclear.
3.1.1.2. Article 7(a)(ii) The morbidity and mortality rates of the disease in animal
populations
Morbidity
Parameter 1 – Prevalence/incidence
For CBPP, it is important to differentiate the clinical appearance (presence of symptoms) from the
presence of infection deﬁned as isolation of Mmm. OIE deﬁnes a CBPP case based on the presence of
Mmm. The most recent outbreaks in Europe occurred in mostly in Portugal (from 1982 to 1999) and in
Italy (from 1990 to 1995) (Regalla et al., 1996). In Portugal, the seroprevalence measured by CFT was
never high with a peak at about 1.2% in 1987 and a progressive decline as control measures were
implemented. As CFT is not speciﬁc, positive CFT sera had to be conﬁrmed using western blotting at
the end of the eradication campaign when the prevalence was close to zero. The regions where the
prevalence was high corresponded to higher animal and farm densities as well as common milking
parlours. In Italy, half of the outbreaks were concentrated in three areas. In these areas, the yearly
herd incidence was about 1,340/100,000, while in the rest of Italy, it amounted to 2/100,000 (Regalla
et al., 1996).
In Africa, the disease is endemic and the local situation depends largely on the control measures
that are implemented. In Ethiopia in the Borena region, 62% of bull batches had at least one
seropositive animal (hence was considered positive), but the individual seroprevalence was very low:
0.4% (Alemayehu et al., 2015). In Mali, a national survey conducted in 2011 on 199 herds totalling
about 8000 sera showed that a very high number of herds had to be considered infected (85%) while
the individual prevalence reached 18%. In northern Cameroon, Wade et al. (2015) found a very high
proportion of lung suspicious lesions (30%) but isolation or polymerase chain reaction (PCR)-positive
results were obtained only from 1.6% to 3.4%, respectively.
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Parameter 2 – Case-morbidity rate (% clinically diseased animals out of infected ones)
The clinical prevalence can be quite low, even in the face of an acute outbreak. A good example of
this fact can be found in a paper from Bygrave that describes the occurrence of a CBPP outbreak at
Archers post in Kenya in 1966 (Bygrave et al., 1968). The decision to slaughter the herd allowed the
study of 2,541 carcasses. During this outbreak, acute clinical signs were limited to less than 50% of
the cattle involved in the epizootic while 90% were infected. The majority of cattle with acute lesions
on necropsy showed typical clinical signs for only about 3 days prior to death. Most cases classed as
‘chronic’ on necropsy had little or no clinical respiratory embarrassment prior to slaughter. The typical
‘soft cough’ of CBPP cattle was not a marked feature; only 25% of animals with acute lesions at
necropsy had this symptom when forced to move. Similar ﬁndings were seen in experimental
‘in-contact’ infections with control animals (Hudson and Turner, 1963). Out of 90 in-contact animals,
57% showed symptoms but more than 75% had typical lesions.
Mortality
Parameter 3 – Case-fatality rate
Reported case-fatality rates observed in the control groups of experimental CBPP reproductions are
highly variable, from 0% to 70%:
Hudson and Turner (1963): 0%, 17%, 18% and 28% in the control groups of four successive
experiments
Gilbert et al. (1970): 0% and 22% in two experiments
Davies et al. (1968): 0%
Hudson (1968a): 18% and 36% in two experiments
Doutre et al. (1972): 73%
Yaya et al. (1999): 50%
These data are obtained from experimental studies, where the conditions were controlled. There
were no antibiotic treatments installed and therefore the mortality observed truly reﬂects what
happened in those experiments. The variability of the observed percentage can be attributed to many
factors:
• The virulence of Mmm strains may vary (although we have no precise information yet on the
exact molecular basis of virulence).
• There is some breed variation of susceptibility (Hudson, 1968b).
• There are obviously a number of predisposing factors that may inﬂuence the outcome of the
infection. CBPP being characterised by an acute inﬂammatory process, every event that
modulates the immune system (co-infections with viruses, parasitic infestation, etc.) may have
an impact on CBPP outcome.
3.1.1.3. Article 7(a)(iii) The zoonotic character of the disease
CBPP is not zoonotic.
3.1.1.4. Article 7(a)(iv) The resistance to treatments, including antimicrobial resistance
Parameter 1 – Resistant strain to any treatment even at laboratory level
All mycoplasmas are naturally resistant to penicillins (absence of a cell wall). Mmm can easily
become resistant to aminosides (based on the creation of a streptomycin resistant variant of the T1/44
vaccine strain obtained after ﬁve passages). The mutation rate conferring resistance to streptomycin,
spectinomycin, novobiocin, erythromycin and tylosin was estimated at 107,5 to 108,3 (Lee et al.,
1987). There is no actual data on the antimicrobial resistance in Mmm strains circulating in Africa.
However, a parallel can be made with Mycoplasma bovis, which is present in Europe and for which a
retrospective study has been performed over a period of 30 years (from 1980 to 2010) in France
(Gautier-Bouchardon et al., 2014). The antimicrobial resistance became:
• substantial for tylosin, tilmicosin, tulathromycin and spectinomycin;
• moderate for enroﬂoxacin, danoﬂoxacin, marboﬂoxacin and oxytetracycline;
• no differences were observed for gamithromycin, tildipirosin, ﬂorfenicol and valnemulin.
Nevertheless, in the European Union (EU), animals are not treated against Mmm infection,
therefore there would not be any signiﬁcant additional danger to animal health as a consequence of
possible development of drug resistance.
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3.1.1.5. Article 7(a)(v) The persistence of the disease in an animal population or the
environment
Animal population
Parameter 1 – Duration of infectious period in animals
The infectious period can be subdivided in the latent phase where no clinical signs are detected and
then the clinical phase (see Parameter 2 below). The clinical stage of the disease can itself be divided
in two stages, the acute and the chronic stage. This was the basis for the development of
compartment models (Lesnoff et al., 2002).
Animals in the acute stage (i.e. animals with evolving pleuropneumonia lesions, which are not
encapsulated) are highly infectious, because of the expectoration of infective droplets. The mean
duration for this phase can be estimated as approximately 1 month (excluding the latent phase),
although it is clear this duration can vary considerably from one case to another.
Animals in the chronic stage of the disease present lesions called sequestra, which are
encapsulated. Mmm can be isolated from these lesions for up to 12 months (Windsor and Masiga,
1977a). The real infectious risk presented by these animals is unknown, but is certainly limited (in the
Lesnoff model, a relative risk of less than 1/50 compared to animals in the acute stage was
considered) (Lesnoff et al., 2002, 2004a).
In natural infections under normal conditions, the infectiousness of the animals may be modulated
by the antibiotic treatments.
Parameter 2 – Presence and duration of latent infection period
There is experimental evidence that Mmm can be detected in the upper respiratory tract from 26 to
40 days before these animals show any symptom (Hudson and Turner, 1963) and this period can last
at least 3 months, as seen with animals that were contaminated by the ‘in-contact’ method (through
exposure of na€ıve animals to animals infected following exposure through intubation) without showing
any overt disease signs (Belli et al., 1989).
Parameter 3 – Presence and duration of the pathogen in healthy carriers
Animals with sequestra may be in a long-term carrier state, which may last up to 1 year (Windsor
and Masiga, 1977a). However, this is based on a single experiment where it was difﬁcult to determine,
when the animal was originally contaminated. A period of 1 year after the last case is required to
declare a zone as ‘free’ according to the OIE.
Environment
Parameter 4 – Length of survival (dpi) of the agent and/or detection of DNA in selected matrices (soil,
water, air) from the environment (scenarios: high and low T)
Mmm is theoretically very fragile as it does not have any cell wall. However, it has a polysaccharidic
pseudocapsule, which may help resist harsh conditions especially through the formation of bioﬁlms
(McAuliffe et al., 2008).
Temperature has an effect only when it is higher than 43°C and UV light has a deleterious effect on
Mmm (loss of three logs in 7 min and 9 logs in 37 min) (Hudson, 1968c). This means that in Europe,
temperature will not be responsible for Mmm inactivation but exposure to sunlight may.
3.1.1.6. Article 7(a)(vi) The routes and speed of transmission of the disease between
animals, and, when relevant, between animals and humans
Routes of transmission
Parameter 1 – Types of routes of transmission from animal to animal (horizontal, vertical)
The main route of transmission is by direct contact between an infective animal (either
presymptomatic or in the acute phase of the disease) and a na€ıve one. The transmission occurs
through infected droplets released during coughing. This mode of natural transmission explains the
lung localisation of the lesions of CBPP although artiﬁcial inoculations through other routes may lead to
inﬂammatory lesions in other organs (Willems reaction after subcutaneous inoculations, peritonitis,
myositis, etc.).
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Animals in the chronic stage of the disease may still harbour Mmm, but their real infectivity is
unknown. Mycoplasma shedding might be intermittent and at low level. These animals may be
responsible for the long-term persistence of CBPP and prolonged risk.
There is a single publication relating the presence of Mmm in the urine of infected cattle which may
account for indirect transmissions (Masiga et al., 1972). Transmission to na€ıve cattle through artiﬁcially
contaminated hay was successful (Windsor and Masiga, 1977b), but it involved Mmm concentrations
that are unrelated to ﬁeld reality. Previous studies to infect na€ıve animals with contaminated premises
failed (Hudson, 1972).
Long-distance contaminations with droplets that are transported by the winds have been
suspected in Italy (Giovannini et al., 2000). In Lombardy, in 1990–1993, there was a spatial
segregation of CBPP non-infected and infected herds, in the absence of direct contacts, which is in
clear favour of an indirect transmission of CBPP. In fact, the long-distance transport of droplets that
are contaminated by mycoplasmas has already been proven for Mycoplasma hyopneumoniae over
5–10 km (Otake et al., 2010).
Vertical transmission of CBPP has not been recorded. Fetuses can be infected by Mmm although
they do not present lesions (Windsor et al., 1972) but this usually results in abortions. In an
experimental infection, an in-contact infected cow gave birth to a calf, which died rapidly with a
polyarthritis and from which Mmm could be isolated (Belli et al., 1989).
Mmm has been isolated from the sperm of infected cattle in Italy (Stradaioli et al., 1999) but also
with sheath washing in Portugal (Goncalves, 1994). This is in accordance with the normal occurrence
of mycoplasmas in epithelia tissues where they can scavenge metabolites they are unable to
synthesise and where they ﬁnd a protective environment (37°C in a humid atmosphere). There seems
to be no reports with evidence of CBPP sexual transmission.
The presence of Mmm in ticks collected from CBPP cases was described in Angola (Mendes, 1959).
Such ﬁnding was conﬁrmed later on in Kenya and it was shown that the ticks contained about 103 log
Mmm per tick. However, experimental transmission through infected ticks failed.
To summarise, the routes of transmission based on their importance are as follows:
• Direct contact is the main source of contamination/transmission (airborne)
• Distant spread may be responsible for some cases of transmission (airborne)
• Vectors are not considered to play any role in the transmission of CBPP
• Fomites are not considered to play any role in the transmission of CBPP
• Animal products do not play any role in the transmission of CBPP
• Environmental contamination is considered negligible due to the fragility of mycoplasmas.
Parameter 2 – Types of routes of transmission between animals and humans (direct, indirect, including
food-borne)
This is not applicable.
Speed of transmission
Parameter 3 – Incidence between animals and, when relevant, between animals and humans
Reported transmission rates range from 0.07 to 0.13 (Mariner et al., 2006) and 0.03 per week
(Lesnoff et al., 2002).
Parameter 4 – Transmission rate (beta) (from R0 and infectious period) between animals and, when
relevant, between animals and humans
There are very few publications on R0 evaluation for CBPP. Accurate estimation is complicated by
the fact that this value can vary a lot according to variation in Mmm strain virulence, breed
susceptibility, and other unknown predisposing factors.
Determination of transmission rates (beta) and calculation of R0 were done (Balenghien et al.,
2004, 2005). Using an epidemiological SEIR model for the spread of CBPP combined with the dynamic
of seroconversion to describe serological diagnostic data from an experimental vaccine trial, it was
found that the transmission contact rates for subclinical, clinical and chronic infective states are
respectively, 0.084/N, 0.45 and 0.14/N per animal per day, where N is the herd population size, and
the basic reproductive number corresponding to this trial (N = 28) is R0 = 27 (Balenghien et al., 2005).
In different conditions, the expression of R0 is given by, R0 = b0 (29 + 14N) where b0 (ranging
between 0.01 and 0.45) is the transmission rate of clinical infected animals (Balenghien et al., 2004).
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R0 was estimated at 1.24–2 in an agropastoral husbandry system in West Ethiopia (Lesnoff et al.,
2004b). The model that was used to estimate this parameter was validated through follow-up of more
than 1,600 animals over a period of 2 years. Another estimate of R0 achieved with another model and
serological results obtained in southern Sudan (Mariner et al., 2006) ranged from 3.2 to 4.
The discrepancy between the two evaluations can have multiple origins. The husbandry type differs
a lot, the serological tests used were different (CFT for Mariner et al. (2006) and competitive enzyme-
linked immunosorbent assay (cELISA) for Lesnoff et al. (2004b)) and the models also varied. In fact
Mariner’s evaluation may be biased as the sero-positivity with the CFT test does not correlate with
prevalence rate but more to the incidence of CBPP during the past three months (CFT detecting mostly
short-lived IgMs).
3.1.1.7. Article 7(a)(vii) The absence or presence and distribution of the disease in the
Union, where the disease is not present in the Union, the risk of its introduction
into the Union
Presence and distribution
Parameter 1 – Map where the disease is present in the EU
Today (2017), there are no CBPP cases reported in the EU, while the last case was recorded in
Portugal in 1999.
Parameter 2 – Type of epidemiological occurrence (sporadic, epidemic, endemic) at MS level
Sporadic cases of CBPP have been reported in Europe with 10–20 years interval, i.e. 1935; 1956;
1967; 1982–1996. These are considered resurgences and not due to importation (Dupuy et al., 2012).
This was demonstrated by a ‘haplotype’ network analysis showing that all the Mmm strains of
European origin derived from a single ancestor and were positioned in an individual branch completely
independent from the other Mmm strains of African origin. The most recent Mmm strains of European
origin (posterior to 1980) differed from the ancestor and the Mmm strain isolated in 1967, at the
French-Spanish border, by a large DNA deletion.
Risk of introduction
Parameter 3 – Routes of possible introduction
The possible routes of introduction to the Union include import of live animals, semen and embryos
from infected countries.
Parameter 4 – Number of animal moving and/or shipment size
The import of cattle into the EU from CBPP-infected countries or zone is prohibited.
Parameter 5 – Duration of infectious period in animal and/or commodity
The infectious period is considered to be maximum 1 year in a chronic carrier. See Section 3.1.1.5
Parameters 2 and 3.
Parameter 6 – List of control measures at border (testing, quarantine, etc.)
The most important control measures at borders include ban on the import of live cattle or water
buffaloes or yak from infected countries or zones. Testing is not a feasible, as there is no accurate test
that could detect all subclinical infected animals and quarantine should be very long.
Parameter 7 – Presence and duration of latent infection and/or carrier status
No precise data are available.
Latent carriers can shed Mmm for up to 3 months without showing any overt sign of disease.
However, active shedders showing symptoms will become positive in serology (CFT ﬁrst and then
cELISA). Seropositivity does not last very long and chronic carriers may survive and become
seronegative. CFT detected antibodies (IgMs mostly) will wane sooner than cELISA detected
antibodies.
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Parameter 8 – Risk of introduction
The risk of introduction is affected by
• Importation of live susceptible animals from supposedly free countries which do not have an
efﬁcient surveillance system in place.
This risk is considered extremely unlikely as the importation of live cattle into the EU is strictly
regulated and controlled (meat products are not a CBPP risk), especially for cattle originating from
sub-Saharan Africa where CBPP exists today. There could be an indirect risk if cattle (or embryos, see
below) from infected countries are imported into other non-EU countries where surveillance is not
optimal and where CBPP remains undetected or unreported.
• Importation of contaminated semen or embryos which may be used in na€ıve cows and which
may give birth to contaminated calf.
This risk is also considered extremely unlikely. However, it should be considered especially if there
are some programs for the conservation of endangered indigenous African cattle breeds.
• Resurgence of Mmm strains that may have escaped detection by the classical surveillance system.
Such strains may circulate unnoticed in the form of low virulent strains that could circulate in
susceptible animals as they will not induce any lesion nor any seroconversion. Or these strains
could circulate in non-susceptible species, such as small ruminants and then contaminate cattle
on rare occasions. Such possibility exists as Mmm was isolated from small ruminants in India
(Srivastava et al., 2000) while no outbreak was detected or notiﬁed in cattle at this time.
This risk can be considered as extremely unlikely or very unlikely at the most. However, it cannot
be disregarded as such events have occurred in the past with CBPP resurgence in Europe at
10–20 years interval (Dupuy et al., 2012). The only way to mitigate this risk would be to perform
regular testing of Mycoplasma strains isolated from cattle but also from small ruminants in the
countries/regions that were affected during the last CBPP outbreaks (Portugal, Spain and Italy). This
procedure may not be considered compulsory to obtain a CBPP-free status as CBPP surveillance is
usually performed at the slaughterhouse with meat inspection detecting suspicious CBPP lesions.
However, isolation of mycoplasmas is the only way to spot low pathogenicity strains.
In 2016, only few countries were declared ofﬁcially free of CBPP by the OIE (Figure 1).
In Europe, only Switzerland, Portugal and France applied and were granted that status.
CBPP freedom according to the OIE means absence of Mycoplasma mycoides subsp. mycoides
and not simply the absence of disease.
Source: OIE
Figure 1: Recognised countries free of CBPP by the OIE
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3.1.1.8. Article 7(a)(viii) The existence of diagnostic and disease control tools
Diagnostic tools
Parameter 1 – Existence of diagnostic tools
Direct detection of Mmm
• Isolation of Mmm is quite easy if the laboratory has some experience in Mycoplasma isolation
and that the quality of the sample is adequate (no bacterial contamination, no antibiotic
residue). Mmm can grow in 24–48 h. Pleural ﬂuid from acute cases can contain up to 109.5
mycoplasmas per ml. For example, isolation of Mycoplasma strains circulating in ruminants is
one of the surveillance tool put in place in France through the ‘Vigimyc’ network. Mycoplasma
isolated in regional labs are sent to a reference laboratory (ANSES Lyon) where their identity
will be veriﬁed to rule out the possibility of Mmm strains circulating unapparent in the herds
(Chazel et al., 2010). To our knowledge, such comprehensive network for Mycoplasma
identiﬁcation does not exist in other MS.
• Speciﬁc PCR and quantitative PCR (Q-PCR) have been developed. The OIE Manual of Standards
mentions those of Bashiruddin et al. (1994), Dedieu et al. (1994) and Miserez et al. (1997), and
for Q-PCR (Gorton et al., 2005; Fitzmaurice et al., 2008; Lorenzon et al., 2008; Vilei and Frey,
2010; Schnee et al., 2011).
• Some isothermal loop-mediated ampliﬁcation systems (Mair et al., 2013) have been developed
but have yet to be validated in the ﬁeld.
• There is a PCR that can detect speciﬁcally the T1 vaccine strains (Lorenzon et al., 2000).
• Once isolated, Mmm strains can exquisitely be characterised at the genome level, for example
by an ‘extended MLSA’ system involving 53 genes (Dupuy et al., 2012). Since then, the
sequencing technology has been improved a lot (for example the PacBio NGS). Today de-novo
whole genome sequencing will still be difﬁcult because of large DNA duplications in the Mmm
genome but comparison with a reference can easily be performed.
Indirect detection
There are two prescribed serological tests: the CFT and the cELISA.
• The CFTwas developed as early as 1930 in Japan (Yamagiwa et al., 1930) and was popularised in
Australia by Campbell and Turner (1936). The CFT played a major role for the detection of
infected animals during the eradication of CBPP in Australia which was based on the repetitive
test-and-slaughter plus vaccination strategy (Newton, 1992; Turner, 2011). It also played a major
role in Europe during the last outbreaks in 1967 (at the French-Spanish border), in 1982 (again at
the French-Spanish border) and in 1993 (Portugal and Italy) for the slaughter of positive herds.
The CFT is not strictly speciﬁc (97–99%) and false-positive results are to be expected when large
enquiries are performed, for example in Switzerland (St€ark et al., 1995). When CBPP prevalence is very
low or zero, CFT-positive samples can usually be conﬁrmed using the western-blotting technique.
There are few CFT kit producers in Europe. CIRAD was still producing and selling such kits but may
not do so anymore because of the small and erratic demand. Stocks of antigen are nevertheless still
kept in case of an emergency situation (this antigen is very stable).
• A speciﬁc competitive ELISA has been developed (Le Goff and Thiaucourt, 1998). Its speciﬁcity
lies in the use of a monoclonal antibody. Its speciﬁcity is higher than 99.5% when the test is
performed under quality procedures. It is difﬁcult to determine its sensitivity. It is lower than
the CFT at an early stage after infection (as CFT detects mostly immunoglobulins M (IgMs))
but it is higher at a later stage, notably to detect chronic cases (Amanfu et al., 2000; Muuka
et al., 2011; Tardy et al., 2011; Sery et al., 2015).
This test is produced by IDEXX ref: P05410-10 and all batches are controlled by CIRAD before release.
It is important to note that CFT and cELISA are both considered herd tests. They will not be able to
detect latent Mmm shedders, which do not display circulating antibodies and they will have a low
sensitivity for the detection of chronic carriers (Mycoplasma-induced antibodies are short-lived). A
practical consequence is that serological results should be expressed in ‘herd prevalence’ with sampling
frames including the random selection of herds in the various compartments but a targeted selection
of animals in the chosen herds to increase the sensitivity of the results.
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• Western-blotting can be used as a conﬁrmatory test to rule out false positivity, notably by the
CFT (Goncalves et al., 1998) and especially at the end of an eradication programme when the
predictive value of CFT positive results is very low.
Control tools
Parameter 2 – Existence of control tools
There are four control measures for CBPP: slaughter, control of movement, antibiotic treatments
and vaccination.
A strategy for the control/eradication of CBPP will inevitably be a combination of these control
measures that must be applied either at individual or herd level or in a timely spatiotemporal way.
Slaughter and control of animal movement will not be discussed as they are not speciﬁc for CBPP.
Antibiotic treatments
Although they are banned when CBPP is diagnosed, there are great chances that these antibiotic
treatments will be put in place by veterinarians in the face of respiratory signs in cattle herds before
any precise diagnostic is obtained. There are great chances that CBPP signs will be confused with
other bacterial infections such as pasteurellosis or Mycoplasma bovis infections.
These antibiotic treatments may be quite effective and they will lead to a lack of detection and
possible unnoticed expansion of the disease unless some speciﬁc lesions are discovered after slaughter.
Unfortunately, autopsies are not regularly performed for cattle that have died and the bodies are very
often disposed of directly.
Vaccines
Vaccines have been developed as soon as the infective nature of CBPP was proven. The ﬁrst
‘vaccines’ were in fact inoculation procedures that mimicked the inoculation procedures for small-pox.
In Africa, these inoculations were performed at the bridge of the nose (Blancou, 1996) while in
Europe it was performed at the tip of the tail (Willems, 1852).
Live vaccines have been obtained by empirical attenuation after a number of passages in vitro or
in ovo. The most well-known vaccine strains are the V5 developed in Australia (Hudson, 1968c),
inoculated at the tip of the tail, which played a major role in the reduction of CBPP prevalence before
stamping out procedures were put in place to achieve eradication. The KH3J that was obtained in
southern Sudan (Juba) (Hudson, 1965) and the most popular one, T1/44, developed in East Africa by
Sheriff and Piercy (Sheriff and Piercy, 1952; Piercy, 1958) after 44 passages in embryonated eggs. A
streptomycin resistant derivative of T1/44, T1sr, was obtained some time later that could be
introduced together with the rinderpest vaccine (Provost, 1969).
The main drawback of these vaccines is that some of them have a residual virulence (V5, T1/44)
which would make them unacceptable by today’s standards in Europe. Another drawback is the short
duration of immunity they induce (6 months for T1sr and 1 year for T1/44) which did not allow the
eradication of CBPP (Thiaucourt et al., 2000) while the combined campaigns achieved eradication of
rinderpest, notably in Africa.
However, they have the great advantage that they do not induce the production of long-lasting
seroconversion, allowing the detection of affected herds by the CFT or cELISA provided the sampling is
performed at least 3 months after vaccination.
Numerous new types of vaccines are in the process of development but very few have been
validated so far due to a lack of funding and interest by donor agencies. At CIRAD, an inactivated
vaccine based on a modiﬁed Mmm strain, which is deleted for an immunogenic antigen, and therefore,
a DIVA vaccine, has been developed. It received a preliminary experimental validation during the
‘VACNADA’ project ﬁnanced by the EU (project ended in 2011).
3.1.2. Article 7(b) The impact of diseases
3.1.2.1. Article 7(b)(i) The impact of the disease on agricultural and aquaculture
production and other parts of the economy
The level of presence of the disease in the Union
Parameter 1 – Number of MSs where the disease is present
None.
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The loss of production due to the disease
Parameter 2 – Proportion of production losses (%) by epidemic/endemic situation
The impact in the EU if introduced is not known. Such information is impossible to predict as there
are too many variables at stake.
In Africa, CBPP was re-introduced in Tanzania in 1994. It rapidly spread to the whole country in
spite of vaccination efforts aiming at preventing the spread of the disease to the South. The direct
losses due to cattle mortality, vaccination campaigns and surveillance were estimated at more than
11 million dollars (Msami et al., 2001) for a cattle population of 10 million. The vaccination campaigns
that were performed at that time did not succeed in preventing the spread and CBPP is now prevalent
in the whole country. Losses are less conspicuous as the disease evolves in an enzootic manner.
Botswana, which faced the same reoccurrence of CBPP, decided to adopt a strict stamping out
policy in the CBPP affected zone (320,000 heads slaughtered) with an estimated cost of 100 million
dollars.
In other parts of Africa, where CBPP occurs in an enzootic form, the annual losses due to that
disease in 12 countries were estimated at about EUR 45 million (Tambi et al., 2006).
These ﬁgures are certainly not transposable to Europe.
The potential impact is likely from the cost of the eradication campaigns and restrictions to trade
rather than the direct costs.
In the best of scenarios, the surveillance systems, which are based on the passive surveillance of
lung lesions observed at slaughterhouses, are very efﬁcient in all Member States and new CBPP
outbreaks will be detected very rapidly before the disease has time to spread. In that case, the cost
will be strictly limited to the few herds that will have to be slaughtered.
This is theoretically feasible. Lesions of CBPP are quite conspicuous (unilateral pleuropneumonia
with profuse exudate or sequestra), serological tests are available for conﬁrmation and cultivation of
Mmm is quite easy with a number of European laboratories that are able to cultivate and identify
them.
However, this is not likely to happen. It is quite probable that CBPP outbreaks will not be spotted
immediately and animals will be given antibiotic treatments masking the symptoms. Animals that die
may not be inspected and go directly for disposal. The efﬁciency of the surveillance system mostly
relies on the detection of suspicious lesions at the slaughterhouses (OIE accepted strategy as more
than 95% of animals are slaughtered in such slaughterhouses). However, the technicians may not be
sensitised to the CBPP risk as the EU did not experience any outbreak since 1999. It is not known if all
EU veterinary services organise training sessions that include observation of CBPP lesions.
The ﬁnal cost will therefore depend on:
• the extension of the disease before it is spotted;
• the swiftness of response and the control measures implemented.
In France, there is a national survey of Mycoplasma strains isolated in ruminants to possibly detect
the presence of Mmm (Vigimyc network coordinated by ANSES) even in the absence of suspicions.
3.1.2.2. Article 7(b)(ii) The impact of the disease on human health
CBPP is not a zoonosis.
3.1.2.3. Article 7(b)(iii) The impact of the disease on animal welfare
Parameter 1 – Severity of clinical signs at case level and related level and duration of impairment
CBPP is very painful due to the pleurisy in the acute stage and then due to the ﬁbrous tissue
connecting the costal and lung pleura once the lesions have healed. In Africa, chronic carriers are
called ‘lungers’ and usually lag behind the rest of the herd during movements. Therefore, there may
be an important impact on welfare, although this would not relate to a large number of animals, since
the within-herd prevalence of infection is usually low.
3.1.2.4. Article 7(b)(iv) The impact of the disease on biodiversity and the environment
Biodiversity
CBPP does not affect wildlife.
AHL assessment on contagious bovine pleuropneumonia
www.efsa.europa.eu/efsajournal 13 EFSA Journal 2017;15(10):4995
Environment
Parameter 3 – Capacity of the pathogen to persist in the environment and cause mortality in wildlife
CBPP does not affect wildlife and Mmm does not persist in the environment.
3.1.3. Article 7(c) Its potential to generate a crisis situation and its potential use
in bioterrorism
An introduction of CBPP into the EU may have huge consequences for intra-Community trade and
EU exports, thus having the potential to generate at least a commercial crisis.
Parameter 1 – Listed in OIE/CFSPH classiﬁcation of pathogens
Not listed in the CFSPH for potential bioterrorism and agroterrorism agents (CFSPH, 2016).
The disease is present in the OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals
2017 (OIE, 2014).
Parameter 2 – Listed in the Encyclopaedia of Bioterrorism Defence of Australia Group
Although CBPP is listed in the list of human and animal pathogens and toxins for export control
from the Australia Group, it is not listed in the Encyclopaedia of Bioterrorism Defence of Australia
Group.
Parameter 3 – Included in any other list of potential bio-agroterrorism agents
It is not listed.
3.1.4. Article 7(d) The feasibility, availability and effectiveness of the following
disease prevention and control measures
3.1.4.1. Article 7(d)(i) Diagnostic tools and capacities
Availability
Parameter 1 – Ofﬁcially/internationally recognised diagnostic tool, OIE certiﬁed
The cELISA is produced by IDEXX ref: P05410-10.
Kits are produced under ISO 9001, all kit batches are quality controlled externally by CIRAD which
performs the test under ISO 17025 accreditation by COFRAC.
International proﬁciency testing is organised regularly by CIRAD.
For the CFT, the availability of kits is more questionable. However, such kits were produced in the
past in Europe during the last outbreaks in 1982–1996 and there is no doubt that these kits could be
produced again.
The cELISA may be more reliable because of its speciﬁcity and facility for quality monitoring.
Isolation and PCR can also be performed under accreditation although there is no kit available so
far (because of the absence of a market).
Effectiveness
Parameter 2 – Se and Sp of diagnostic test
The accuracy of the cELISA at individual level: speciﬁcity is near 100% when the test is performed
under quality management, while the sensitivity varies by disease stage and time of sampling after the
onset of outbreak. It can be 60–70% for up to 6 months and much lower after 1 year.
This is the reason why the epidemiological unit to be considered should be the herd.
The accuracy of the cELISA at herd level: speciﬁcity remains near 100% when the test is performed
under quality management (considering a true-positive sample reaching a value above the cut-off plus
the uncertainty of measurement). Sensitivity is much higher when targeting animals in the herd, which
have suffered from suspicious signs during the past 12 months, hence improving the sensitivity of
detection, although a speciﬁc estimate of the herd sensitivity is available.
Feasibility
Parameter 3 – Type of sample matrix to be tested (blood, tissue, etc.)
Blood can be used for testing.
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3.1.4.2. Article 7(d)(ii) Vaccination
Availability
Parameter 1 – Types of vaccines available on the market (live, inactivated, DIVA, etc.)
In Europe, no vaccine is authorised for sale.
Live vaccines are available in Africa. Two strains are available, T1/44 which was developed in 1952
(Sheriff and Piercy, 1952) by attenuating the original strain with 44 passages in embryonated eggs.
This strain has been empirically attenuated; hence, it is not known which genetic modiﬁcations
induced its attenuation nor which genes (and gene expression) are necessary for inducing protection.
In fact a ‘good CBPP’ vaccine is a compromise between attenuation, which allows using them as a
vaccine that does not induce inﬂammation at the site of inoculation, and keeping a minimum of
virulence to trigger an immune response in the vaccinated animals.
This strain has a certain residual virulence and may induce a local swelling at the site of injection
when na€ıve animals are vaccinated for the ﬁrst time. The percentage of reacting animals is very
variable and may reach exceptionally up to 17% (in Zambia in 1971) (Revell, 1973). Local reactions do
not occur after re-vaccinations. A streptomycin resistant variant of T1/44, called T1sr, has been
developed later on to permit the development of a combined vaccine protecting against rinderpest and
CBPP (Provost, 1969). T1sr is void of any residual virulence.
The minimum dose for these vaccines is 107 viable organisms but higher doses (108) are
recommended by the OIE to take into account the probable loss of titres along the chain between the
production plant and the vaccinated cattle.
The protective immune response is considered cell-mediated and there is no strict correlation
between the level of antibodies that can be detected in an animal and its immune status (protected vs
susceptible).
NB: CIRAD has been developing another type of CBPP vaccine based on the use of a modiﬁed
pathogenic strain (one gene coding for an immunogenic protein has been deleted and the antibiotic
resistance gene has also been deleted subsequently). The ﬁnal product is killed antigen which is
formulated into an oil-emulsion as an adjuvant. Therefore, it is a DIVA vaccine as antibody rise after
vaccination can be followed with the cELISA. Detection of infected animals could be performed by
using the deleted antigen. However, the companion serological test is not developed yet.
This vaccine has passed a preliminary validation process in Mali within the framework of the
VACNADA project (funded by the EU: VACNADA, online).
However, CIRAD could not obtain any grant to ﬁnish the validation of this product which is
therefore remaining as a ‘potential vaccine’ not available on the market.
Parameter 2 – Availability/production capacity (per year)
Availability for the live vaccines such as T1/44 is there as the master seed is kept at CIRAD and
producing batches require only classical means (fermenters and freeze driers).
There are about seven vaccine producers located in Africa. At least one of them is located in a
CBPP-free country (the Botswana Veterinary Institute) and in the future MCI in Morocco may be in a
position to produce such vaccines under Good manufacturing practices (GMP).
There are about 40–50 million doses of CBPP vaccines that are produced in Africa annually. This is
far less than the number of susceptible cattle population in the affected countries (more than
350 million).
Effectiveness
Parameter 3 – Field protection as reduced morbidity (as reduced susceptibility to infection and/or to
disease)
The protection afforded by a single injection is sometimes limited (70% protection at the herd
level); however, this level increases after subsequent re-vaccinations and vaccinated herds are
considered completely protected. This is the reason why CBPP vaccination campaigns in Africa should
target 100% of the susceptible population and plan vaccination activities over successive years.
In fact, the protection rate may be higher but it is difﬁcult to evaluate in experiments that always
include a limited number of animals with a lot of factors that are not completely controlled (virulence
of the challenging strain notably).
The vaccination failures that are sometimes reported in Africa are usually resulting from an
improper implementation of the vaccination campaigns. The absence of consistent serological markers
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after vaccination does not allow a seromonitoring of the vaccination campaigns efﬁcacy. This is a real
problem for the follow-up of the vaccination campaigns in Africa.
Parameter 4 – Duration of protection
The duration of protection using T1sr is 6 months, while it is 1 year using T1/44.
Feasibility
Parameter 5 – Way of administration
Vaccine administration is subcutaneous.
3.1.4.3. Article 7(d)(iii) Medical treatments
Availability
Parameter 1 – Types of drugs available on the market
Usually forbidden for CBPP, but the following antibiotics may be used: long acting tetracyclines,
macrolides such as gamithromycin or ﬂuoroquinones.
Parameter 2 – Availability/production capacity (per year)
This is not applicable.
Effectiveness
Parameter 3 – Therapeutic effects on the ﬁeld (effectiveness)
Although being effective in curing symptoms, antibiotics may not be able to prevent the persistence
of Mmm in treated animals. This was one of the reasons for prohibiting their use for CBPP in the
framework of an eradication of the disease. However, antibiotic treatments will certainly reduce
dramatically the excretion and should be considered in strategies combining vaccination to protect
susceptible animals and antibiotic treatments to reduce shedding and contamination risk.
Feasibility
Parameter 4 – Way of administration
Depending on the antimicrobial used, some products are injected intramuscularly while others are
injected subcutaneously.
3.1.4.4. Article 7(d)(iv) Biosecurity measures
Availability
Parameter 1 – Available biosecurity measures
Prohibiting import of live animals from infected countries is the primary biosecurity measure to
reduce the risk of introduction. The detection of CBPP suspicious cases into a shipment of animals to
be imported into a CBPP-free zone such as the EU should be followed by a strict quarantine until CBPP
is conﬁrmed. In that case, the immediate slaughter of the shipment should be implemented.
Effectiveness
Parameter 2 – Effectiveness of biosecurity measures in preventing the pathogen introduction
The ban of import of live cattle from infected zones has effectively protected Europe from CBPP since
time immemorial (the 1990 outbreaks were due to resurgence of the disease and not from an importation).
The destruction of infected herds effectively removes the Mmm shedder animals and cut the
contamination routes.
Hence, the effectiveness of the whole campaign will depend on the ability to detect all positive
herds. The combination of two serological tests such as the CFT and cELISA should enhance the
sensitivity of serological testing at herd level. Besides, these two tests can be performed under quality
assurance which should ensure more reliable results.
An extreme example is Botswana, where it was decided to slaughter the whole cattle population in
the contaminated zone (300,000 heads) to get rid of CBPP and regain a freedom status allowing
exports to Europe. The strategy was very efﬁcient. No CBPP outbreaks were detected after
repopulation with cattle from CBPP-free countries (notably South Africa) (Masupu et al., 1997).
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Feasibility
Parameter 3 – Feasibility of biosecurity measures
The feasibility of biosecurity measures including import and movement restrictions depend on the
efﬁcacy of surveillance systems in place in the various countries.
3.1.4.5. Article 7(d)(v) Restrictions on the movement of animals and products
Availability
Parameter 1 – Available movement restriction measures
As CBPP is mostly transmitted by direct contact between an infected animal and a susceptible one,
the restriction of movement of live animal will certainly prevent a further spread of the infected zone.
The key parameter is therefore to deﬁne an infected zone that includes all infected farms. This may be
difﬁcult because CBPP incubation period is quite long. Many animals may have been moved away
during this period before CBPP is deﬁnitely conﬁrmed.
Effectiveness
Parameter 2 – Effectiveness of restriction of animal movement in preventing the between farm spread
Not completely fool-proofed as long distance contamination has to be considered. However, once a
CBPP outbreak has been identiﬁed, it has to be expected that sick animals (which are the real Mmm
shedders) will be detected and eliminated rapidly, hence reducing dramatically the distance
contamination risk.
Feasibility
Parameter 3 – Feasibility of restriction of animal movement
The feasibility of restriction of animal movement depends primarily on the existence of laws
pertaining to the management of crisis situations when CBPP (or any other regulated disease) appears.
Each MS should have a contingency plan ready for such occurrence. This is requested by the OIE
when countries are applying for an ofﬁcial freedom status.
These plans can beneﬁt from a booklet prepared by the FAO in 2002 (Geering and Amanfu, 2002).
3.1.4.6. Article 7(d)(vi) Killing of animals
Availability
Parameter 1 – Available methods for killing animals
Animals can be brought to slaughterhouses provided they are transported in sealed trucks (but this
may be against animal welfare rules). Such a procedure was implemented by Australia. Animals from
the infected zone were transported by train, and not by hoof, to slaughterhouses.
Effectiveness
Parameter 2 – Effectiveness of killing animals (at farm level or within the farm) for reducing/stopping
spread of the disease
The killing of animals is very effective. Different strategies have been used worldwide.
In Australia, the initial strategy, at farm level, involved the slaughter of all CFT-positive animals
(mobile laboratories were available) and the vaccination of the others. This procedure was repeated
every three months as vaccination antibodies disappear quite rapidly. At the end of the eradication
campaign, when herd prevalence was drastically reduced, vaccination was stopped and replaced by a
strict herd stamping out policy (Newton, 1992).
In Europe, they slaughter targeted positive herds and vaccination has never been allowed (Regalla
et al., 1996).
In Botswana, the slaughter involved the whole cattle population in the infected zone and was
indeed effective as described above (Masupu et al., 1997).
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Feasibility
Parameter 3 – Feasibility of killing animals
As stated in Parameter 2 above, this slaughter policy has already been implemented with success in
Europe and it allowed Portugal and Italy to regain their freedom status after some years. This is
naturally costly but what is sure is that without any coordinated strategy CBPP would gradually spread
to the whole of Europe.
What really matters is to have a reliable surveillance system in place that allows the detection of
CBPP outbreaks very rapidly. A swift response, based on the slaughter of infected herds is the most
likely to be successful and with the best cost/beneﬁt result.
If the detection of CBPP is performed at a later stage, then naturally the cost of a slaughter policy
may be too high (both ﬁnancially and socially). Various strategies may then be discussed.
This strategy will involve the four classical measures: slaughter, restriction of animal movement,
treatment and vaccination.
3.1.4.7. Article 7(d)(vii) Disposal of carcasses and other relevant animal by-products
Availability
Parameter 1 – Available disposal option
As indirect contamination through fomites is negligible and CBPP is not a zoonotic risk, carcasses
can be used for human consumption.
Effectiveness
Parameter 2 – Effectiveness of disposal option
Carcasses do not present any risk and can be manipulated in any abattoir.
Feasibility
Parameter 3 – Feasibility of disposal option
No speciﬁc precaution is needed when manipulating carcasses. CBPP is not a zoonosis and there are
usually no farms at the vicinity of slaughterhouses which minimise the risk of any aerosol transmission.
3.1.5. Article 7(e) The impact of disease prevention and control measures
3.1.5.1. Article 7(e)(i) The direct and indirect costs for the affected sectors and the
economy as a whole
If CBPP was to be identiﬁed in a MS, the ﬁrst action to be implemented would be to deﬁne an
‘infected zone’ (IZ) and a ‘surveillance zone’ (SZ) around it.
Parameter 1 – Cost of control (e.g. treatment/vaccine, biosecurity)
CBPP control is not an option right now in the EU as treatments or vaccination alone cannot lead to
an eradication of the disease and would not allow the contaminated EU MS to regain their CBPP-
freedom status.
This policy could be eventually modiﬁed if an inactivated DIVA vaccine was available. Such vaccines
could be used in the IZ to prevent CBPP spread and to restrict culling to infected herds. The drawback
of such a policy is that export of cattle may be prohibited from that zone until vaccination is stopped
and sufﬁcient time is allowed to be sure that Mmm does not circulate in that zone. However, products
like meat or milk could be exported safely.
Parameter 2 – Cost of eradication (culling, compensation)
For the time being, there are only two culling strategies that can be implemented in the EU. Both
are based on the culling of herds and not individuals as for CBPP the epidemiological unit that makes
sense is the herd.
• Culling the whole herd population in the IZ. This would be the safest policy if the IZ is restricted
in size (i.e. if the surveillance network has been sufﬁciently efﬁcient to detect CBPP cases very
rapidly). The cost of this strategy is easily calculated (mean cost of cattle in the zone multiplied
by the total number of animals in the infected zone). These costs do not take into account
indirect costs which may be linked to the loss of valuable genetic material for example.
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• Culling infected herds while monitoring the status of the other herds.
The cost would then be equal to the culling costs added to monitoring costs. Culling costs will
depend primarily on the percentage of herds which are found positive. Multiple cycles of monitoring and
culling will have to be implemented, roughly at 3 months interval (time needed to allow animals in the
incubation period to show symptoms and to be detected either by clinical surveillance or by serology).
The cost of monitoring in the IZ will also depend on the chosen strategy (all animals tested in the
herd or targeted sampling of animals that are either old or that showed suspicious symptoms in
the past months). The safest strategy would be to test all sampled sera with the two prescribed tests,
the CFT and the cELISA, as it would increase the sensitivity of detection at the herd level. Herds in
which there are only few positives by the CFT should be conﬁrmed by western blotting to reduce the
number of negative herds to be culled (a likely issue at the end of the eradication process).
The estimated serological testing cost at the laboratory may vary from EUR 5–15 per test on top of
which the sampling has to be added (this cost may vary a lot from country to country but estimates
have already been issued for other diseases as sampling is not disease speciﬁc).
Parameter 3 – Cost of surveillance and monitoring
These costs will also depend on the strategy that is implemented in the SZ. There is no consensus
on the size of the SZ (10 km around the IZ?). This may naturally be modiﬁed after an epidemiological
enquiry is performed and a mapping of animal movements to and fro the IZ is obtained.
• Syndromic surveillance has to be implemented in that zone as to report any respiratory signs
that could be linked to CBPP. In that case, serology will have to be implemented in the
suspected herd. In case of positivity the IZ and SZ will have to be modiﬁed accordingly.
• Serological testing could also be implemented in the SZ but maybe not on all herds.
Parameter 4 – Trade loss (bans, embargos, sanctions) by animal product
It is likely that all exports of live animals from the infected country will be banned, unless the said
country can prove that only a zone (according to the OIE deﬁnition) is affected. The trade loss will
then be depending on the importance of export of live animals from that zone.
Parameter 5 – Importance of the disease for the affected sector (% loss or € lost compared to
business amount of the sector)
As CBPP is not present in the EU, this importance cannot be estimated so far.
3.1.5.2. Article 7(e)(ii) The societal acceptance of disease prevention and control
measures
The social acceptance of the slaughter strategy is difﬁcult to predict. It will mostly depend on the
extent of the CBPP infected zone and the number of herds which will have to be culled. Owners may
be reluctant to accept slaughter as antibiotic treatments may be used and that vaccines are available
(both of which are forbidden by the regulations).
3.1.5.3. Article 7(e)(iii) The welfare of affected subpopulations of kept and wild animals
Parameter 1 – Welfare impact of control measures on domestic animals
There is theoretically no welfare issue as humane slaughtering will be implemented.
Parameter 2 – Wildlife depopulation as control measure
There is no welfare issue for wildlife as these species do not play any role in the epidemiology of
CBPP and will not be impacted by the control measures.
3.1.5.4. Article 7(e)(iv) The environment and biodiversity
Environment
Parameter 1 – Use and potential residuals of biocides or medical drugs in environmental compartments
(soil, water, feed, manure)
Control measures may have an impact on the environment only if antibiotics are included in the control
strategy. This is not the case now in most European countries which ban antibiotic treatments for CBPP.
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Biodiversity
Parameter 2 – Mortality in wild species
Wildlife species are not known to be affected.
3.2. Assessment according to Article 5 criteria
This section presents the results of the expert judgement on the criteria of Article 5 of the AHL
about CBPP (Table 1). The expert judgement was based on Individual and Collective Behavioural
Aggregation (ICBA) approach described in detail in the opinion on the methodology (EFSA AHAW
Panel, 2017). Experts have been provided with information of the disease fact-sheet mapped into
Article 5 criteria (see supporting information, Annex A), based on that the experts indicate their Y/N or
‘na’ judgement on each criterion of Article 5, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted as
described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation of
the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
3.2.1. Non-consensus questions
This section displays the assessment related to each criterion of Article 5 where no consensus was
achieved in form of tables (Table 2). The proportion of Y, N or na answers are reported, followed by
the list of different supporting views for each answer.
Table 1: Outcome of the expert judgement on the Article 5 criteria for contagious bovine
pleuropneumonia
Criteria to be met by the disease:
According to AHL, a disease shall be included in the list referred to in point (b) of paragraph 1 of
Article 5 if it has been assessed in accordance with Article 7 and meets all of the following
criteria
Final
outcome
A(i) The disease is transmissible Y
A(ii) Animal species are either susceptible to the disease or vectors and reservoirs thereof
exist in the Union
Y
A(iii) The disease causes negative effects on animal health or poses a risk to public health due
to its zoonotic character
Y
A(iv) Diagnostic tools are available for the disease Y
A(v) Risk-mitigating measures and, where relevant, surveillance of the disease are effective
and proportionate to the risks posed by the disease in the Union
Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points A(i)–A(v), the disease needs to fulﬁl at least one of the
following criteria
B(i) The disease causes or could cause signiﬁcant negative effects in the Union on animal
health, or poses or could pose a signiﬁcant risk to public health due to its zoonotic
character
Y
B(ii) The disease agent has developed resistance to treatments and poses a signiﬁcant danger
to public and/or animal health in the Union
N
B(iii) The disease causes or could cause a signiﬁcant negative economic impact affecting
agriculture or aquaculture production in the Union
Y
B(iv) The disease has the potential to generate a crisis or the disease agent could be used for
the purpose of bioterrorism
NC
B(v) The disease has or could have a signiﬁcant negative impact on the environment,
including biodiversity, of the Union
N
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
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Reasoning supporting the judgement
Supporting Yes:
• CBPP may have huge consequences and generate a crisis for intra-community trade and EU
exports, if introduced in EU.
Supporting No:
• It is not listed as a bioterrorism or agroterrorism agent.
3.2.2. Outcome of the assessment of contagious bovine pleuropneumonia
according to criteria of Article 5(3) of the AHL on its eligibility to be listed
As from the legal text of the AHL, a disease is considered eligible to be listed as laid down in Article
5 if it fulﬁls all criteria of the ﬁrst set from A(i) to A(v) and at least one of the second set of criteria
from B(i) to B(v). According to the assessment methodology (EFSA AHAW Panel, 2017), a criterion is
considered fulﬁlled when the outcome is ‘Yes’. According to the results shown in Table 1, CBPP
complies with all criteria of the ﬁrst set and with two criteria of the second set, therefore it is
considered eligible to be listed for Union intervention as laid down in Article 5(3) of the AHL.
3.3. Assessment according to Article 9 criteria
This section presents the results of the expert judgement on the criteria of Annex IV referring to
categories as in Article 9 of the AHL about CBPP (Tables 3, 4, 5, 6 and 7). The expert judgement was
based on ICBA approach described in detail in the opinion on the methodology. Experts have been
provided with information of the disease fact-sheet mapped into Article 9 criteria (see supporting
information, Annex A), based on that the experts indicate their Y/N or ‘na’ judgement on each criterion
of Article 9, and the reasoning supporting their judgement.
The minimum number of judges in the judgement was 12. The expert judgement was conducted
as described in the methodological opinion (EFSA AHAW Panel, 2017). For details on the interpretation
of the questions, see Appendix B of the methodological opinion (EFSA AHAW Panel, 2017).
Table 3: Outcome of the expert judgement related to the criteria of Section 1 of Annex IV
(category A of Article 9) for contagious bovine pleuropneumonia
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is not present in the territory of the Union OR present only in exceptional cases
(irregular introductions) OR present only in a very limited part of the territory of the Union
Y
2.1 The disease is highly transmissible N
2.2 There are possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects multiple species of kept and wild animals OR single species of kept
animals of economic importance
Y
2.4 The disease may result in high morbidity and signiﬁcant mortality rates Y
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health,
including epidemic or pandemic potential OR possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial
costs, mainly related to its direct impact on the health and productivity of animals
NC
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour markets N
Table 2: Outcome of the expert judgement related to criterion 5 B(iv)
Question
Final
outcome
Response
Y (%) N (%) na (%)
B(iv) The disease has the potential to generate a crisis or the
disease agent could be used for the purpose of bioterrorism
NC 25 75 0
NC: non-consensus; number of judges: 12.
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Table 4: Outcome of the expert judgement related to the criteria of Section 2 of Annex IV
(category B of Article 9) for contagious bovine pleuropneumonia
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic character
AND (at the same time) several Member States or zones of the Union are free of the disease
N
2.1 The disease is moderately to highly transmissible Y
2.2 There are possibilities of airborne or waterborne or vector-borne spread Y
2.3 The disease affects single or multiple species Y
2.4 The disease may result in high morbidity with in general low mortality NC
At least one criterion to be met by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, including
epidemic potential OR possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of the Union, causing substantial costs,
mainly related to its direct impact on the health and productivity of animals
NC
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large numbers
of animals
Y
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to
those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
Table 5: Outcome of the expert judgement related to the criteria of Section 3 of Annex IV
(category C of Article 9) for contagious bovine pleuropneumonia
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
1 The disease is present in the whole OR part of the Union territory with an endemic character N
2.1 The disease is moderately to highly transmissible Y
2.2 The disease is transmitted mainly by direct or indirect transmission Y
2.3 The disease affects single or multiple species Y
2.4 The disease usually does not result in high morbidity and has negligible or no mortality AND
often the most observed effect of the disease is production loss
N
At least one criterion to bemet by the disease:
In addition to the criteria set out above at points 1–2.4, the disease needs to fulﬁl at least one of the following criteria
3 The disease has a zoonotic potential with signiﬁcant consequences on public health, or
possible signiﬁcant threats to food safety
N
4 The disease has a signiﬁcant impact on the economy of parts of the Union, mainly related to
its direct impact on certain types of animal production systems
N
5(a) The disease has a signiﬁcant impact on society, with in particular an impact on labour
markets
N
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large
numbers of animals
Y
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection
of endangered species or breeds, including the possible disappearance or long-term
damage to those species or breeds
N
Colour code: green = consensus (Yes/No), yellow = non-consensus (NC).
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3.3.1. Non-consensus questions
This section displays the assessment related to each criterion of Annex IV referring to the
categories of Article 9 of the AHL where no consensus was achieved in form of tables (Tables 8 and 9).
The proportion of Y, N or `na0 answers are reported, followed by the list of different supporting views
for each answer.
Reasoning supporting the judgement
Supporting Yes:
• Mortality can be variable. It is usually low, but could be high according to the virulence of the
strain of Mmm and to the susceptibility of the host breed. Morbidity ranges from 5% to 68%.
Supporting No:
• Both morbidity and mortality can have high levels, and in untreated animals mortality can be
up to 70%.
5(b) The disease has a signiﬁcant impact on animal welfare, by causing suffering of large numbers
of animals
Y
5(c) The disease has a signiﬁcant impact on the environment, due to the direct impact of the
disease OR due to the measures taken to control it
N
5(d) The disease has a signiﬁcant impact on a long-term effect on biodiversity or the protection of
endangered species or breeds, including the possible disappearance or long-term damage to
those species or breeds
N
Colour code: green = consensus (Yes/No).
Table 6: Outcome of the expert judgement related to the criteria of Section 4 of Annex IV
(category D of Article 9) for contagious bovine pleuropneumonia
Criteria to be met by the disease:
The disease needs to fulﬁl all of the following criteria
Final
outcome
D The risk posed by the disease in question can be effectively and proportionately mitigated by
measures concerning movements of animals and products in order to prevent or limit its
occurrence and spread
Y
The disease fulﬁls criteria of Sections 1, 2, 3 or 5 of Annex IV of AHL Y
Colour code: green = consensus (Yes/No).
Table 7: Outcome of the expert judgement related to the criteria of Section 5 of Annex IV
(category E of Article 9) for contagious bovine pleuropneumonia
Diseases in category E need to fulﬁl criteria of Sections 1, 2 or 3 of Annex IV of AHL and/or
the following:
Final
outcome
E Surveillance of the disease is necessary for reasons relating to animal health, animal welfare,
human health, the economy, society or the environment (If a disease fulﬁls the criteria as in
Article 5, thus being eligible to be listed, consequently category E would apply.)
Y
Colour code: green = consensus (Yes/No).
Table 8: Outcome of the expert judgement related to criterion 2.4 of Article 9
Question
Final
outcome
Response
Y (%) N (%) na (%)
2.4 (cat. B) The disease may result in high morbidity with in general
low mortality
NC 25 75 0
NC: non-consensus; number of judges: 12.
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Reasoning supporting the judgement
Supporting Yes:
• If introduced and spread uncontrolled, there could be a signiﬁcant impact on the economy.
• As there is no treatment, there could be high morbidity and mortality. The yearly herd-
incidence in Italy was 1.34% in the 1990s.
Supporting No:
• The individual seroprevalence appears to be normally low, not a large number of animals is
clinically affected; thus, it would be more a welfare issue for the affected animals.
3.3.2. Outcome of the assessment of criteria in Annex IV for contagious bovine
pleuropneumonia for the purpose of categorisation as in Article 9 of the
AHL
As from the legal text of the AHL, a disease is considered ﬁtting in a certain category (A, B, C, D or
E corresponding to point (a) to point (e) of Article 9(1) of the AHL) if it is eligible to be listed for Union
intervention as laid down in Article 5(3) and fulﬁls all criteria of the ﬁrst set from 1 to 2.4 and at least
one of the second set of criteria from 3 to 5(d) as shown in Tables 3–7. According to the assessment
methodology (EFSA AHAW Panel, 2017), a criterion is considered fulﬁlled when the outcome is ‘Yes’.
A description of the outcome of the assessment of criteria in Annex IV for CBPP for the purpose of
categorisation as in Article 9 of the AHL is presented in Table 10.
According to the assessment here performed, CBPP complies with the following criteria of the
Sections 1–5 of Annex IV of the AHL for the application of the disease prevention and control rules
referred to in points (a) to (e) of Article 9(1):
Table 9: Outcome of the expert judgement related to criterion 4 of Article 9
Question
Final
outcome
Response
Y (%) N (%)
na
(%)
4 (cat. A, B) The disease has a signiﬁcant impact on the economy of the
Union, causing substantial costs, mainly related to its direct
impact on the health and productivity of animals
NC 50 50 0
NC: non-consensus; number of judges: 12.
Table 10: Outcome of the assessment of criteria in Annex IV for contagious bovine
pleuropneumonia for the purpose of categorisation as in Article 9 of the AHL
Category
Article 9 criteria
1° set of criteria 2° set of criteria
1 2.1 2.2 2.3 2.4 3 4 5a 5b 5c 5d
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1) To be assigned to category A, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment CBPP complies with criteria 1, 2.2, 2.3 and 2.4,
but not with criterion 2.1. To be eligible for category A, a disease needs to comply
additionally with one of the criteria of the second set (3, 4, 5a–d) and CBPP complies with
criterion 5b, but not with criteria 3, 5a, 5c and 5d and the assessment is inconclusive on
compliance with criterion 4.
2) To be assigned to category B, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment CBPP complies with criteria 2.1, 2.2 and 2.3,
but not with criterion 1 and the assessment is inconclusive on compliance with criterion 2.4.
To be eligible for category B, a disease needs to comply additionally with one of the criteria
of the second set (3, 4, 5a–d) and CBPP complies with criterion 5b, but not with criteria 3,
5a, 5c and 5d and the assessment is inconclusive on compliance with criterion 4.
3) To be assigned to category C, a disease needs to comply with all criteria of the ﬁrst set
(1, 2.1–2.4) and according to the assessment CBPP complies with criteria 2.1, 2.2 and 2.3,
but not with criteria 1 and 2.4. To be eligible for category C, a disease needs to comply
additionally with one of the criteria of the second set (3, 4, 5a–d) and CBPP complies only
with criterion 5b.
4) To be assigned to category D, a disease needs to comply with criteria of Sections 1, 2, 3 or 5
of Annex IV of the AHL and with the speciﬁc criterion D of Section 4, with which CBPP
complies.
5) To be assigned to category E, a disease needs to comply with criteria of Sections 1, 2 or 3 of
Annex IV of the AHL and/or the surveillance of the disease is necessary for reasons relating to
animal health, animal welfare, human health, the economy, society or the environment. The
latter is applicable if a disease fulﬁls the criteria as in Article 5, with which CBPP complies.
3.4. Assessment of Article 8
This section presents the results of the assessment on the criteria of Article 8(3) of the AHL about
CBPP. The Article 8(3) criteria are about animal species to be listed, as it reads below:‘3. Animal
species or groups of animal species shall be added to this list if they are affected or if they pose a risk
for the spread of a speciﬁc listed disease because:
a) they are susceptible for a speciﬁc listed disease or scientiﬁc evidence indicates that such
susceptibility is likely; or
b) they are vector species or reservoirs for that disease, or scientiﬁc evidence indicates that such
role is likely’.
For this reason, the assessment on Article 8 criteria is based on the evidence as extrapolated from
the relevant criteria of Article 7, i.e. the ones related to susceptible and reservoir species or routes of
transmission, which cover also possible role of biological or mechanical vectors.1 According to the
mapping, as presented in Table 5, Section 3.2 of the scientiﬁc opinion on the ad hoc methodology
(EFSA AHAW Panel, 2017), the main animal species to be listed for contagious bovine
pleuropneumonia according to the criteria of Article 8(3) of the AHL are as displayed in Table 11.
Table 11: Main animal species to be listed for contagious bovine pleuropneumonia according to
criteria of Article 8 (source: data reported in Section 3.1.1.1)
Class Order Family Genus/Species
Susceptible Mammalia Artiodactyla Bovidae Cattle (Bos taurus), yak (Bos gruniensis),
water buffalo (Bubalus bubalis),
goat (Capra hircus), sheep (Ovis aries),
African buffalo (Sincerus cafer)
Lagomorpha Leporidae not speciﬁed
Reservoir Not identiﬁed
Vectors None
1 A vector is a living organism that transmits an infectious agent from an infected animal to a human or another animal. Vectors
are frequently arthropods. Biological vectors may carry pathogens that can multiply within their bodies and be delivered to new
hosts, usually by biting. In mechanical vectors, the pathogens do not multiply within the vector, which usually remains infected
for shorter time than in biological vectors.
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4. Conclusions
TOR 1: for each of those diseases an assessment, following the criteria laid down in Article 7 of
the AHL, on its eligibility of being listed for Union intervention as laid down in Article 5(3) of the AHL;
• According to the assessment here performed, CBPP complies with all criteria of the ﬁrst set
and with two criteria of the second set and therefore can be considered eligible to be listed for
Union intervention as laid down in Article 5(3) of the AHL.
TOR 2a: for each of the diseases which was found eligible to be listed for Union intervention, an
assessment of its compliance with each of the criteria in Annex IV to the AHL for the purpose of
categorisation of diseases in accordance with Article 9 of the AHL;
• According to the assessment here performed, CBPP meets the criteria as in Sections 4 and 5 of
Annex IV of the AHL, for the application of the disease prevention and control rules referred to
in points (d) and (e) of Article 9(1) of the AHL.
TOR 2b: for each of the diseases which was found eligible to be listed for Union intervention, a list
of animal species that should be considered candidates for listing in accordance with Article 8 of the
AHL.
• According to the assessment here performed, the animal species that can be considered to be
listed for CBPP according to Article 8(3) of the AHL are species of the family Bovidae as
susceptible, as reported in Table 11 in Section 3.4 of the present document.
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Abbreviations
AHAW EFSA Panel on Animal Health and Welfare
AHL Animal Health Law
CBPP contagious bovine pleuropneumonia
cELISA competitive enzyme-linked immunosorbent assay
CFT complement ﬁxation tests
GMP Good manufacturing practices
ICBA Individual and Collective Behavioural Aggregation
Ig immunoglobulin
IZ infected zone
Mmm Mycoplasma mycoides subsp. mycoides
MS Member State
OIE World Organization for Animal Health
PCR polymerase chain reaction
SZ surveillance zone
ToR Terms of Reference
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Annex A – Mapped fact-sheet used in the individual judgement on
contagious bovine pleuropneumonia
Annex A can be found in the online version of this output (‘Supporting information’ section):
https://doi.org/10.2903/j.efsa.2017.4995
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